Abstract
Opioid peptides have the potential to be pharmaceutical agents for the treatment of pain because they modulate nociceptive pathways at supraspinal, spinal and peripheral levels. Unfortunately, peptides are generally hydrophilic compounds and therefore unable to cross the blood-brain barrier (BBB) by passive diffusion to reach the central nervous system (CNS) in an amount sufficient to activate appropriate receptors. Endomorphins (EMs) belong to the class of endogenous opioids eliciting the strongest analgesic effect, but only after direct administration to the CNS. Extensive research is in progress to better understand the relationships between EM structure and bioavailability. This article deals with the recent investigations that allow the design of stable and neuroactive EM analogs with enhanced brain passage and uptake.
Keywords: Opioid peptides, opioid receptors, analgesia, bioavailability, passive diffusion, peptide permeability.
Medicinal Chemistry
Title:Bioavailability of Endomorphins and the Blood-brain Barrier- A Review
Volume: 10 Issue: 1
Author(s): Renata Perlikowska and Anna Janecka
Affiliation:
Keywords: Opioid peptides, opioid receptors, analgesia, bioavailability, passive diffusion, peptide permeability.
Abstract: Opioid peptides have the potential to be pharmaceutical agents for the treatment of pain because they modulate nociceptive pathways at supraspinal, spinal and peripheral levels. Unfortunately, peptides are generally hydrophilic compounds and therefore unable to cross the blood-brain barrier (BBB) by passive diffusion to reach the central nervous system (CNS) in an amount sufficient to activate appropriate receptors. Endomorphins (EMs) belong to the class of endogenous opioids eliciting the strongest analgesic effect, but only after direct administration to the CNS. Extensive research is in progress to better understand the relationships between EM structure and bioavailability. This article deals with the recent investigations that allow the design of stable and neuroactive EM analogs with enhanced brain passage and uptake.
Export Options
About this article
Cite this article as:
Perlikowska Renata and Janecka Anna, Bioavailability of Endomorphins and the Blood-brain Barrier- A Review, Medicinal Chemistry 2014; 10 (1) . https://dx.doi.org/10.2174/15734064113099990040
DOI https://dx.doi.org/10.2174/15734064113099990040 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A New Frontier in the Treatment of Cancer: NK-1 Receptor Antagonists
Current Medicinal Chemistry When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development
Current Pharmaceutical Design Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases
Current Medicinal Chemistry NK Cell, Monocyte and Non T Cell Biomarkers as Prognostic Indicators in Cancer Immunotherapy
Current Cancer Therapy Reviews Targeting IAPs as An Approach to Anti-Cancer Therapy
Current Topics in Medicinal Chemistry β-lactam Structured, 4-(4-(Methylsulfonyl)phenyl)-1-pentyl-3-phenoxyazetidin-2-one: Selectively Targets Cancerous B Lymphocyte Mitochondria
Anti-Cancer Agents in Medicinal Chemistry Applications of High Content Screening in Life Science Research
Combinatorial Chemistry & High Throughput Screening Virus, Oncolytic Virus and Human Prostate Cancer
Current Cancer Drug Targets Poly(ADP-Ribosylation): Beneficial Effects of Its Inhibition
Current Enzyme Inhibition Mechanisms to Inhibit Matrix Metalloproteinase Activity: Where are we in the Development of Clinically Relevant Inhibitors?
Recent Patents on Anti-Cancer Drug Discovery Auraptene: A Natural Biologically Active Compound with Multiple Targets
Current Drug Targets The Use of Transient Expression Systems for the Rapid Production of Virus-like Particles in Plants
Current Pharmaceutical Design Cellular and Molecular Mechanisms of Tumor-Induced T-Cell Tolerance
Current Cancer Drug Targets The Possible Role of Infertility Drugs in Later Malignancy: A Review
Current Medicinal Chemistry Pharmacometrics in Dose Finding or Dose Optimization of Anti-Retroviral and Anti-Tubercular Drugs
Infectious Disorders - Drug Targets The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
Current Clinical Pharmacology Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Genetics and Epigenetics of Lung Cancer: Mechanisms and Future Perspectives
Current Cancer Therapy Reviews The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications
Current Genomics Heparin Affin Regulatory Peptide: A New Target for Tumour Therapy?
Current Cancer Drug Targets